145 related articles for article (PubMed ID: 24166368)
1. Split Gaussia luciferase for imaging ligand-receptor binding.
Luker KE; Luker GD
Methods Mol Biol; 2014; 1098():59-69. PubMed ID: 24166368
[TBL] [Abstract][Full Text] [Related]
2. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.
Luker K; Gupta M; Luker G
Biotechniques; 2009 Jul; 47(1):625-32. PubMed ID: 19594447
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation.
Luker KE; Mihalko LA; Schmidt BT; Lewin SA; Ray P; Shcherbo D; Chudakov DM; Luker GD
Nat Med; 2011 Dec; 18(1):172-7. PubMed ID: 22138753
[TBL] [Abstract][Full Text] [Related]
4. Dual-Color Luciferase Complementation for Chemokine Receptor Signaling.
Luker KE; Luker GD
Methods Enzymol; 2016; 570():119-29. PubMed ID: 26921944
[TBL] [Abstract][Full Text] [Related]
5. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
6. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
8. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions.
Ray P; Lewin SA; Mihalko LA; Lesher-Perez SC; Takayama S; Luker KE; Luker GD
Biochem J; 2012 Mar; 442(2):433-42. PubMed ID: 22142194
[TBL] [Abstract][Full Text] [Related]
9. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
10. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
11. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.
Singh AK; Arya RK; Trivedi AK; Sanyal S; Baral R; Dormond O; Briscoe DM; Datta D
Cytokine Growth Factor Rev; 2013 Feb; 24(1):41-9. PubMed ID: 22989616
[TBL] [Abstract][Full Text] [Related]
12. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
Costantini S; Raucci R; De Vero T; Castello G; Colonna G
Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
[TBL] [Abstract][Full Text] [Related]
13. Imaging chemokine receptor dimerization with firefly luciferase complementation.
Luker KE; Gupta M; Luker GD
FASEB J; 2009 Mar; 23(3):823-34. PubMed ID: 19001056
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Mediated Protein Tagging with Nanoluciferase to Investigate Native Chemokine Receptor Function and Conformational Changes.
White CW; Caspar B; Vanyai HK; Pfleger KDG; Hill SJ
Cell Chem Biol; 2020 May; 27(5):499-510.e7. PubMed ID: 32053779
[TBL] [Abstract][Full Text] [Related]
15. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
16. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
[TBL] [Abstract][Full Text] [Related]
17. Class A G protein-coupled receptors assemble into functional higher-order hetero-oligomers.
Gao X; Enten GA; DeSantis AJ; Majetschak M
FEBS Lett; 2021 Jul; 595(14):1863-1875. PubMed ID: 34032285
[TBL] [Abstract][Full Text] [Related]
18. CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons.
Abe P; Mueller W; Schütz D; MacKay F; Thelen M; Zhang P; Stumm R
Development; 2014 May; 141(9):1857-63. PubMed ID: 24718993
[TBL] [Abstract][Full Text] [Related]
19. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
20. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues.
Hoffmann F; Müller W; Schütz D; Penfold ME; Wong YH; Schulz S; Stumm R
J Biol Chem; 2012 Aug; 287(34):28362-77. PubMed ID: 22736769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
